Last edition
News about "Lilly"
Innovent Collaborates with Lilly to Develop New Medicines in Oncology and Immunology
The agreement grants Lilly an exclusive licence to develop and commercialise the programmes worldwide outside Greater China, while Innovent retains rights in Greater China.
Lilly | 09/02/2026 | By News Bureau
Lilly in Advanced Talks to Acquire Ventyx Biosciences in Deal Worth Over USD 1 Billion
Eli Lilly & Company is in advanced discussions to acquire Ventyx Biosciences in a deal valued at more than USD 1 billion, according to reports citing people familiar with the matter. The acquisition talks have attracted strong investor interest, with Ventyx shares rising sharply following the news.
Lilly | 07/01/2026 | By Darshana | 142
ABL Bio Receives Upfront Payment and Equity Investment from Lilly for Grabody Platform
ABL Bio has secured a total of USD 55 million in funding from Lilly, including a USD 40 million upfront payment and a USD 15 million equity investment, under a license, research and collaboration agreement to advance R&D and expand indications for its Grabody platform.
Lilly | 26/12/2025 | By News Bureau
Lilly Partners with NVIDIA to Build AI Supercomputer for Drug Discovery and Delivery
Eli Lilly has partnered with NVIDIA to build AI supercomputer, aimed at accelerating the discovery and delivery of new medicines. The collaboration will leverage advanced AI capabilities to identify, optimise, and validate novel molecules, with additional applications in manufacturing, medical imaging, and enterprise AI solutions.
Lilly | 31/10/2025 | By Dineshwori | 252
Lilly's Omvoh Shows Early, Sustained Relief in Bowel Urgency for Ulcerative Colitis
Lilly’s Phase 3b LUCENT-URGE results show that Omvoh (mirikizumab-mrkz) provides early and sustained improvements in bowel urgency in ulcerative colitis. The study is the first in inflammatory bowel disease to assess urgency across severity, frequency, and stool deferral time.
Lilly | 28/10/2025 | By Dineshwori | 194
Magnet Biomedicine and Lilly to Develop Novel Molecular Glue Medicines
The collaboration will leverage Magnet's TrueGlue™ discovery platform to identify molecular glues capable of inducing protein proximity and cooperativity, enabling novel mechanisms of action to address difficult-to-drug targets spanning multiple diseases with unmet medical need.
Lilly | 01/03/2025 | By Aishwarya | 589
Lilly Signs Deal with EVA Pharma to Expand Access to baricitinib
This collaboration is part of the Lilly 30x30 initiative, which aims to improve access to quality health care for 30 million people living in resource-limited settings annually by 2030.
Lilly | 05/09/2024 | By Aishwarya | 532
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy